Cancer screening re-visited again

An article by Melinda Beck in today’s issue of The Wall Street Journal discusses the complex topic of screening, “over-diagnosis”, and over-treatment of low-risk forms of certain cancers (prostate cancer specifically included). … READ MORE …

Metabolic aberrations and risk for prostate cancer

According to a newly published study of data from > 285,000 European males (the Metabolic Syndrome and Cancer Project), men with metabolic aberrations are at slightly less risk for a diagnosis of prostate cancer compared with men who have normal levels of metabolic factors … but their risk for prostate cancer-specific mortality is similar. … READ MORE …

How patients and others react to prostate cancer diagnosis and treatment

According to a media release issued earlier today by ZERO — The End of Prostate Cancer in conjunction with Ferring Pharmaceuticals Inc., “Prostate cancer impacts sex lives more than any other aspect of patients’ lives.” … READ MORE …

The less you know, the harder the decisions about treatment …

In one more of those utterly unsurprising research findings, a study of newly diagnosed patients has shown that poor patient knowledge about the nature of prostate cancer is associated with “decisional conflict” leading to stress and anxiety given the uncertainty associated with the relative “value” of the many possible management options. … READ MORE …

Results of the RADAR trial at 7.4 years of follow-up

The RADAR trial (also known as TROG 03.04) was a randomized trial of 6 months of androgen deprivation therapy (ADT) + radiation therapy versus 18 months of ADT + radiotherapy, with or without additional zoledronic acid therapy, in men with intermediate- and high-risk, locally advanced prostate cancer. … READ MORE …

Short-term outcomes after prostate cancer diagnosis and treatment in France

An article available in full on the Medscape web site provides an overview of short-term outcomes of > 43,000 men diagnosed with prostate cancer in France in 2009 and followed for 2 years based on data in the French national health insurance information system (SNIIRAM). You do need to register with Medscape to be able to read the article (but registration is free). … READ MORE …

To quest and test (or not to quest at all)

On The New York Times‘s “Well” blog site today. Dr. Barak Gaster takes on the complex issue of how doctors need to get better at talking to patients about the pros and cons of PSA testing. And there very definitely are pros and cons! I kid you not.

Follow

Get every new post delivered to your Inbox.

Join 1,175 other followers